Taken together, IL-1 supplied by tumor-infiltrating immune cells may be sufficient to provide a greater growth advantage for BCa tumors in the presence of tamoxifen versus fulvestrant anti-estrogen. The gene discussed is IL1B; the disease is neoplasm.